



## Pharvaris Announces Data Highlighting Deucricitbant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

October 16, 2024

ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- [Pharvaris](#) (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows:

**American College of Allergy, Asthma, & Immunology's Annual Scientific Meeting (ACAAI)**, Boston, October 24-28, 2024. Seven abstracts have been accepted for e-Poster presentation:

- **Poster:** Long-Term Safety and Efficacy of Oral Deucricitbant for Hereditary Angioedema Prophylaxis: CHAPTER-1 Open-Label Extension Study  
**Speaker:** John Anderson, M.D.  
**Format:** e-Poster (R102)  
**Date, Time:** Friday, Oct. 25, 2:00-2:15 p.m. EDT  
**Location:** Monitor 21, Exhibit Hall A
- **Poster:** Long-Term Treatment of Hereditary Angioedema Attacks With Oral Deucricitbant: RAPIDe-2 Extension Study Results  
**Speaker:** John Anderson, M.D.  
**Format:** e-Poster (R103)  
**Date, Time:** Friday, Oct. 25, 2:15-2:30 p.m. EDT  
**Location:** Monitor 21, Exhibit Hall A
- **Poster:** Development Of A Novel Kinin Biomarker Assay For Characterization Of Bradykinin-Mediated Disorders  
**Speaker:** Evangelia Pardali, Ph.D.  
**Format:** e-Poster (R088)  
**Date, Time:** Friday, Oct. 25, 2:30-2:45 p.m. EDT  
**Location:** Monitor 20, Exhibit Hall A
- **Poster:** Development of a HMWK Capillary Immunoblotting Assay for Characterization of Bradykinin-Mediated Disorders  
**Speaker:** Evangelia Pardali, Ph.D.  
**Format:** e-Poster (R090)  
**Date, Time:** Friday, Oct. 25, 3:00-3:15 p.m. EDT  
**Location:** Monitor 20, Exhibit Hall A
- **Poster:** The Bradykinin Challenge Model In Non-Human Primates Successfully Predicted Efficacious Doses of Deucricitbant in Humans  
**Speaker:** Juan Bravo, Ph.D.  
**Format:** e-Poster (R112)  
**Date, Time:** Friday, Oct. 25, 4:30-4:45 p.m. EDT  
**Location:** Monitor 21, Exhibit Hall A
- **Poster:** CHAPTER-1 Phase 2 Trial of Oral Bradykinin B2 Receptor Antagonist Deucricitbant for Hereditary Angioedema Prophylaxis  
**Speaker:** H. James Wedner, M.D.  
**Format:** e-Poster (R100)  
**Date, time:** Friday, Oct. 25, 5:30-5:45 p.m. EDT  
**Location:** Monitor 20, Exhibit Hall A
- **Poster:** Prophylactic Treatment With Oral Deucricitbant Improves Hereditary Angioedema Disease Control and Health-Related Quality of Life  
**Speaker:** H. James Wedner, M.D.  
**Format:** e-Poster (R101)  
**Date, Time:** Friday, Oct. 25, 5:45-6:00 p.m. EDT  
**Location:** Monitor 20, Exhibit Hall A

**Canadian Society of Allergy and Clinical Immunology (CSACI)**, Banff, Alberta, Canada, November 6-9, 2024. Three abstracts have been accepted for poster presentation.

- **Poster:** Efficacy and Safety of Oral Deucricitibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of HAE Attacks: Results of CHAPTER-1 Phase 2 Trial  
**Speaker:** William H. Yang, M.D., FRCPC, FAAAAI  
**Format:** Poster  
**Date, Time:** Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)
- **Poster:** Long-term safety and efficacy of oral deucricitibant, a bradykinin B2 receptor antagonist, for prophylaxis in HAE: CHAPTER-1 extension study results  
**Speaker:** William H. Yang, M.D., FRCPC, FAAAAI  
**Format:** Poster  
**Date, Time:** Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)
- **Poster:** Long-term efficacy and safety of oral bradykinin B2 receptor antagonist deucricitibant in treatment of HAE attacks: RAPIDe-2 extension study results  
**Speaker:** Hugo Chapdelaine, M.D., FRCPC  
**Format:** Poster  
**Date, Time:** Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)

**Japanese Society of Allergology (JSA)**, Kyoto, Japan, October 18-20, 2024. One abstract has been accepted for oral presentation.

- **Presentation:** Efficacy and safety of oral deucricitibant IR capsule in HAE: RAPIDe-3 phase 3 trial design  
**Speaker:** Prof. Michihiro Hide, M.D., Ph.D.  
**Format:** Oral Presentation  
**Date, Time:** Sunday, Oct. 20, 13:30-14:45 JST (12:30 -1:45 a.m. EDT)

The presentation slides and posters will be available on the Investors section of the Pharvaris website at: <https://ir.pharvaris.com/news-events/events-presentations>.

#### About Pharvaris

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of bradykinin-mediated angioedema effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both prophylactically and on-demand. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucricitibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucricitibant for the prevention of HAE attacks in the coming months. For more information, visit <https://pharvaris.com/>.

Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications [maggie.beller@pharvaris.com](mailto:maggie.beller@pharvaris.com)